

Media Release

Zug, 3 April 2017

HBM Healthcare Investments expects to report a net profit of around CHF 136 million for the financial year 2016/2017 – increase of the net asset value per share of around 15 percent

The net asset value per HBM-share (NAV) increased by 16.2 percent to CHF 155.09 during the last quarter of the financial year ended on 31 March 2017. The share price rose by 12.5 percent to CHF 111.40. The two IPO's of Anaptys Biosciences and ObsEva from the portfolio of private companies contributed to this excellent performance in the final quarter on top of the strong value increase seen for the public companies in the portfolio.

Including the cash distribution of CHF 5.50 per share made in June 2016, the NAV per share rose by 14.5 percent and the share price increased by 17.5 percent during the financial year 2016/2017.

These results are unaudited figures, based on the current state of work on the closing of the annual financial statements. The final annual result will be published on 16 May 2017.

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

HBM Healthcare Investments Ltd

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare
Investments

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | info@hbmhealthcare.com
www.hbmhealthcare.com